leisure time -WSS

leisure time

author：Wikipedia 2025-09-05 06:55:42 - browse：13911

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Death of patient in Alzheimer’s trial raises question of possible risks

WSS

Gene therapy denied for Afghan refugee whose father aided U.S.

Nonprofit, backed by Microsoft, to certify AI tools in health care

The story of mRNA: From a loose idea to a tool that may help curb Covid

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Ascension's ugly legal battle over care for poor patients in Texas

explore

leisure time

Wikipedia

New air purifier tech could be key to improving indoor air quality

Stories you might have missed in 2023: health, science, medicine

Medicare proposal to cover medical devices draws a mixed reaction

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Hepatitis C has a cure — but many Americans still lack access to it

Death of patient in Alzheimer’s trial raises question of possible risks

After affirmative action ruling, medical educators look to 'holistic review'

Death of patient in Alzheimer’s trial raises question of possible risks

hotspot

Nonprofit, backed by Microsoft, to certify AI tools in health care

Donald Trump's relentless attacks on special counsel Jack Smith

Death of patient in Alzheimer’s trial raises question of possible risks

Nonprofit, backed by Microsoft, to certify AI tools in health care

FDA early review: GLP

Merck to acquire Harpoon Therapeutics for $680 million

hotspot

knowledge

explore

hotspot